Clinical Trial

A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma

Study acronym: MOMENTUM
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This is a Phase 2, open-label, single-arm, multicenter study to assess the antimyeloma activity and further characterize the safety, tolerability, PK, and PD of cemsidomide in combination with dexamethasone in participants with relapsed/refractory multiple myeloma (r/r MM).
Protocol Amendment History 2 changes
notable Trial sites expanded: 10 -> 21 locations 2026-08-07
notable Trial sites expanded: 3 -> 10 locations 2026-07-02
Trial Details
NCT Number NCT07284758
Lead Sponsor C4 Therapeutics, Inc.
Conditions Multiple Myeloma, Relapsed/Refractory Multiple Myeloma
Enrollment 100 participants
Start Date 2026-02-18
Primary Completion 2030-03 (estimated)
Study Completion 2030-03 (estimated)
Updated on ClinicalTrials.gov 2026-08-06